TGTX — TG THERAPEUTICS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1001316 ·
Last close
$62.71
Market Cap
$9.48B
52W High
$68.03
52W Low
$26.76
ADV30
1,895,175
Next earnings
2026-11-09
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 240,335,000 199,141,000 21,674,000 7,781,000 1,639,629,000 482,575,000 1,035,546,000
Mar 2026 204,918,000 171,408,000 34,795,000 19,777,000 1,528,837,000 442,209,000 945,706,000
Dec 2025 192,574,000 154,432,000 50,494,000 23,037,000 1,063,253,000 79,148,000 415,233,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$86,256,000
Investing CF
$-23,142,000
Financing CF
$292,227,000
CapEx
$-693,000
Dividends Paid
$0
Buybacks
$-199,990,000
EPS Diluted TTM
$0.66
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-998,994,000
Inventory
$194,319,000
Receivables
$416,821,000
ST Investments
$75,295,000
EBIT TTM
$196,142,000
Pretax Income TTM
$149,552,000
Interest Exp TTM
$46,590,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$897,763,008
EBITDA
$193,040,992
Free Cash Flow
$85,523,000
Enterprise Value
$9,287,474,176
Total Cash
$504,671,008
Total Debt
$754,372,992
Shares Out
151,147,827
Trailing EPS
$0.67
Book Value
$4.08
ROE
18.0%
ROA
9.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 616,287,000 123,324,000 447,179,000 1,063,253,000 415,233,000 648,020,000 -24,772,000
Dec 2024 329,004,000 41,929,000 23,383,000 577,690,000 355,326,000 222,364,000 -40,517,000
Dec 2023 233,662,000 20,633,000 12,672,000 329,587,000 169,085,000 160,502,000 -31,413,000
Dec 2022 2,785,000 -218,316,000 -223,812,000 193,572,000 134,985,000 58,587,000 -176,170,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$799,536,000
NetIncome TTM
$441,490,000
OpCashFlow TTM
—
Assets (Latest)
$1,639,629,000
Forward EPS
$2.55

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $60.00 · spot: $66.12 · call volume: 1,809 · put volume: 121
Expected Move to 2026-12-18: ±$7.58 (11.46%) — implied range $58.54 – $73.70 · ATM straddle on $65.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MDGL MADRIGAL PHARMACEUTICALS, INC. $9.80B $421.99 —
SYRE Spyre Therapeutics, Inc. $8.91B $93.81 —
SMMT Summit Therapeutics Inc. $8.53B $10.67 —
PRAX Praxis Precision Medicines, Inc. $8.53B $305.06 —
RYTM RHYTHM PHARMACEUTICALS, INC. $8.08B $116.61 —

News headlines (Yahoo Finance, 1h cache)

TG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™
2026-11-18 12:30 · Yahoo
TG Therapeutics: 3 Key Takeaways for Long-Term Investors
2026-11-15 02:32 · Yahoo
The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
2026-11-11 06:36 · Yahoo
TG Therapeutics (TGTX) Lifts Revenue Guidance As Investors Ask If The Stock Is Pricey
2026-11-11 03:12 · Yahoo
How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, Novartis
2026-11-10 22:12 · Yahoo
Is Earnings Beat Altering The Investment Case For TG Therapeutics (TGTX)?
2026-11-10 22:11 · Yahoo
TG Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-10 03:11 · Yahoo
TG Therapeutics (TGTX) Q3 2026 Earnings Call Transcript
2026-11-10 02:03 · Yahoo
TG Therapeutics Inc (TGTX) (Q3 2026) Earnings Call Highlights: Revenue Jumps 61% as Guidance ...
2026-11-09 21:07 · Yahoo
What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call
2026-11-09 18:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.